Joanne Aiko Matsubara
Research Classification
Research Interests
Relevant Thesis-Based Degree Programs
Affiliations to Research Centres, Institutes & Clusters
Research Options
Research Methodology
Recruitment
Complete these steps before you reach out to a faculty member!
- Familiarize yourself with program requirements. You want to learn as much as possible from the information available to you before you reach out to a faculty member. Be sure to visit the graduate degree program listing and program-specific websites.
- Check whether the program requires you to seek commitment from a supervisor prior to submitting an application. For some programs this is an essential step while others match successful applicants with faculty members within the first year of study. This is either indicated in the program profile under "Admission Information & Requirements" - "Prepare Application" - "Supervision" or on the program website.
- Identify specific faculty members who are conducting research in your specific area of interest.
- Establish that your research interests align with the faculty member’s research interests.
- Read up on the faculty members in the program and the research being conducted in the department.
- Familiarize yourself with their work, read their recent publications and past theses/dissertations that they supervised. Be certain that their research is indeed what you are hoping to study.
- Compose an error-free and grammatically correct email addressed to your specifically targeted faculty member, and remember to use their correct titles.
- Do not send non-specific, mass emails to everyone in the department hoping for a match.
- Address the faculty members by name. Your contact should be genuine rather than generic.
- Include a brief outline of your academic background, why you are interested in working with the faculty member, and what experience you could bring to the department. The supervision enquiry form guides you with targeted questions. Ensure to craft compelling answers to these questions.
- Highlight your achievements and why you are a top student. Faculty members receive dozens of requests from prospective students and you may have less than 30 seconds to pique someone’s interest.
- Demonstrate that you are familiar with their research:
- Convey the specific ways you are a good fit for the program.
- Convey the specific ways the program/lab/faculty member is a good fit for the research you are interested in/already conducting.
- Be enthusiastic, but don’t overdo it.
G+PS regularly provides virtual sessions that focus on admission requirements and procedures and tips how to improve your application.
ADVICE AND INSIGHTS FROM UBC FACULTY ON REACHING OUT TO SUPERVISORS
These videos contain some general advice from faculty across UBC on finding and reaching out to a potential thesis supervisor.
Supervision Enquiry
Postdoctoral Fellows
Graduate Student Supervision
Doctoral Student Supervision
Dissertations completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest dissertations.
Purpose:Age-related macular degeneration (AMD) is a devastating eye disease causing irreversible vision loss in the elderly. Retinal pigment epithelium (RPE), an important cell type afflicted in AMD, undergoes cell death in the late stages of the disease. Salient factors underlying AMD pathogenesis are aging, drusen components and NLRP3 inflammasome activity. The purpose of this dissertation is to elucidate the molecular interactions among these factors and how they contribute to RPE damage.Methods:The effects of aging on drusen components, in particular the membrane attack complex (MAC) and amyloid beta (Aβ) were examined in rats at different age. To determine the role of MAC in inflammasome activation in RPE, aurin tricarboxylic acid complex (ATAC), was administrated to naïve rats. To understand Aβ’s role in inflammasome activation, Aβ intravitreal injections were made into rat eyes in vivo and Vinpocetine was used to ameliorate the inflammatory responses. An in vitro RPE cell culture model was established to further investigate the relationship between inflammasome and X-chromosome linked inhibitor of apoptosis (XIAP). Statistical significance was set at p ≤ 0.05.Results:An age-dependent increase in MAC, Aβ, and NF-κB activation was observed in the RPE-choroid in vivo. Blocking MAC formation with ATAC led to a prominent reduction in inflammasome activity (caspase-1 cleavage and cytokine secretion), but not in NF-κB activity. Aβ intravitreal injections triggered inflammasome activation evidenced by enhanced caspase-1 cleavage and IL-1β/IL-18 release, which was suppressed by Vinpocetine mediated NF-κB inhibition. The robust inflammasome activity further led to gasdermin D-mediated activation of the pyroptotic pathway and a significant reduction in XIAP, which in turn enhanced IL-18 secretion.Conclusion:Aging is a strong risk factor for AMD, which increases the deposition of MAC and Aβ in the outer retina. The elevated levels of MAC and Aβ are triggers for inflammasome activation. By demonstrating a causal relationship between inflammasome activation and XIAP reduction, this dissertation suggests the precise regulation of XIAP, together with the suppression of MAC and NF-κB, may be crucial for controlling inflammasome activity and hence provides new avenues to prevent AMD.
View record
The full abstract for this thesis is available in the body of the thesis, and will be available when the embargo expires.
View record
Purpose:Age-related macular degeneration (AMD) is a multifactorial degenerative disease that occurs in the central part of the retina − macula. The disease affects approximately one million Canadians and constitutes the number one cause of vision loss after cataract in the elderly. The Y402H polymorphism in the complement factor H (CFH) gene and drusen load are two salient risk factors for AMD. Little is known of the detailed cellular pathway(s) shared by these two factors. Here we investigate their interactions in in vitro models of AMD and in AMD samples. Methods:The biological samples came from 44 dry AMD patients, 23 postmortem eyes and retinal pigment epithelial (RPE) cell models. Drusen load and choroidal thickness in patients were measured using spectral-domain optical coherence tomography. We used analytical techniques including genotyping, Bio-Plex suspension assays, immunohistochemistry, immunofluorescence, reverse transcription PCR, Western blot, flow cytometry and lactate dehydrogenase assay Results:In dry AMD patients, higher systemic levels of interleukin (IL)-6, IL-18, and tumor necrosis factor (TNF)-α were associated with the at-risk CC variant of CFH Y402H polymorphism. IL-1β while not significant, demonstrated a similar trend. Drusen load was inversely correlated with choroidal thickness and visual acuity. Postmortem eyes genotyped with the Y402H risk variant showed significantly increased levels of GM-CSF in vitreous and immunoreactivity for CD68, C5a, IL-18 and TNF-α in Bruch’s membrane and/or choroid. Exposure to complement activation product C5a in RPE cells promoted NF-κB activation and upregulated inflammatory cytokines and growth factors. The drusen component, Aβ, induced complement activation and downregulated the membrane bound complement inhibitor, CD55, leading to sublytic MAC formation in RPE cells, which was inhibited by aurin tricarboxylic acid complex. Conclusion: Two important risk factors for AMD, CFH Y402H polymorphism and drusen load, both promote complement activation. Complement activation can mediate downstream events associated with sublytic changes in RPE, such as proinflammatory cytokine release. These results suggest that complement activation might be the central response to multiple risk factors and the complement activation products may further inflict injury on RPE cells. Complement activation products could be potential therapeutic targets to stop chronic inflammation in AMD.
View record
Master's Student Supervision
Theses completed in 2010 or later are listed below. Please note that there is a 6-12 month delay to add the latest theses.
Purinergic signaling via ATP-activated P2X receptors has been studied in age-related macular degeneration (AMD), where retinal pigment epithelium (RPE) cells release ATP and contribute to inflammation and apoptosis. This study focuses on the less-explored P2X4 receptor alongside the well-studied P2X7 receptor in cultured RPE cells, human post-mortem eyes, and mouse eyes to investigate their potential roles in AMD. Immunocytochemistry indicated expression of P2X4 and P2X7 receptors in cultured ARPE-19 cells (cell surface and intracellular), particularly when permeabilized with Triton X-100. Immunohistochemistry on human post-mortem eyes showed that the P2X4 receptor subtype was the most immunoreactive in the RPE of eyes with soft drusen among the five donor groups. In contrast, the P2X7 receptor subtype was the least immunoreactive in the RPE of eyes with soft drusen among the five donor groups. In support of this, RT-qPCR revealed the presence of P2X4 and P2X7 mRNA in ARPE-19 cells, with P2X4 mRNA showing greater upregulation than P2X7 mRNA. Double immunolabeling using Fab fragments in human post-mortem eyes demonstrated co-localization of P2X4 and P2X7 receptors, particularly within and around choroidal cell nuclei. Spectral unmixing for RPE autofluorescence demonstrated co-localization of P2X4 and P2X7 receptors in the RPE of human post-mortem eyes, particularly within and around RPE cell nuclei. Immunohistochemistry on mouse eyes showed P2X4 and P2X7 immunolabeling in the RPE, choroid, and neuroretina. These findings suggest that P2X4 and P2X7 receptors are co-localized in human and mouse retina, but their expression profiles vary with age, donor group/mouse strain, and retinal degeneration. P2X4 receptors potentially play a role in RPE cells, warranting further investigation into their function and interaction with P2X7 receptors in AMD.
View record
Age-related macular degeneration (AMD) is a multifactorial disease which is characterized by drusen deposits, retinal pigmented epithelium (RPE) atrophy and, in a subset of cases, the formation of choroidal neovascularization lesions. Granzyme B (GzmB) is a serine protease traditionally found within natural killer (NK) cells and promotes apoptosis in target cells. Recently, GzmB has been discovered extracellularly and is implicated in chronic inflammatory disorders such as multiple sclerosis (MS), rheumatoid arthritis (RA) and impaired wound healing. GzmB is present within the outer retina and choroid and is upregulated in human donor eyes with wet AMD. This study hypothesizes that mast cells contain GzmB and release it upon degranulation, contributing to a pro-angiogenic response. In order to test this hypothesis, mast cells were first characterized in the mouse choroid tissue using toluidine blue. Peripheral areas of the mouse choroid/sclera were found to contain more mast cells than the central area. Mast cells were then further explored using immunofluorescence (IF) and found to contain and release GzmB when activated. Choroidal sprouting assays (CSA) using ex-vivo RPE/choroidal/scleral tissue from mice exposed to 48/80, a mast cell activator, confirmed that mast cell degranulation increased angiogenesis. Increases in TGF- β and VEGF-A were observed in the supernatants, illustrating the pro-inflammatory and pro-angiogenic effect of mast cell activation. Application of ketotifen fumarate (KF), a mast cell stabilizer, resulted in dramatically reduced sprouting in the CSA, providing further evidence for the pro-angiogenic impact of mast cell degranulation. In order to investigate which mast cell component(s) contribute to the angiogenic response, a GzmB inhibitor, VTI-1002, was applied and resulted in decreased sprouting in the CSA. Using GzmB-KO animals compared to controls in the CSA, it was found that the global knock-out for GzmB increased choroidal sprouting. These findings support the hypothesis that extracellular GzmB plays a pathogenic role in wet AMD. This study is the first to explore the pathogenic implication of extracellular GzmB in choroidal neovascularization.
View record
Glaucoma is a neurodegenerative eye disease characterized by elevated intraocular pressure (IOP) in the majority of cases, followed by retinal ganglion cell (RGC) loss. Neuroinflammation is an important factor contributing to RGC death during glaucoma pathogenesis. Evidence suggests that NLRP3 (nucleotide-binding oligomerization domain (NOD)-like receptor protein 3) inflammasome activity is associated with IOP-induced RGC death. To investigate whether NLRP3 inflammasome is activated by IOP elevation, the DBA/2J mouse model of glaucoma with age-related IOP elevation was studied. Female mice were sacrificed at 3 or 9 months of age. IOP was measured before sacrifice. NLRP3 inflammasome related proteins and RGC loss were quantified in eye tissues. To further assess whether NLRP3 inflammasome activation contributes to RGC death, mice were treated with 8 weeks of daily oral administration of 30 mg/kg MCC950, a specific small-molecule drug that prevents NLRP3 inflammasome activation.In the 9-month DBA/2J mice, IOP was significantly increased compared to 3-month mice. Concomitantly, protein levels of NLRP3 and cleaved caspase-1 were significantly higher in 9- month DBA/2J. The plasma level of circulating MCC950 (7650±775.3 ng/ml) after 8 weeks of drug administration was above the efficacy threshold (>1000 ng/ml). The MCC950 treated mice retained a higher number of surviving RGCs, exhibited lower levels of NLRP3 expression and caspase-1 cleavage compared to age-matched controls. In this study, we discovered MCC950 treatment inhibits the age-related increase of NLRP3 inflammasome activity and ameliorates RGC loss, suggesting that NLRP3 inflammasome activation is associated with RGC death in this mouse model.
View record
Age-related macular degeneration (AMD) is a poorly understood chronic inflammatory eye disease, which is characterized by the atrophy of retinal pigment epithelium (RPE) and the breakdown of Bruch’s membrane (BM), often leading to the formation of choroidal neovascularization (CNV), a hallmark of the exudative form of AMD. Currently, the effective treatments are anti-vascular endothelial growth factor (VEGF) therapies targeting CNV growth. Few studies have been conducted to explore the functions of Granzyme B (GzmB) in AMD. GzmB is a serine protease, stored in the granules of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), and also expressed by different immune and non-immune cells. It was initially believed to be involved in immune-targeted cell death, and recently many studies have revealed an additional role and an extracellular function in several chronic inflammatory disorders, such as asthma, multiple sclerosis (MS), and rheumatoid arthritis (RA). Whether extracellular GzmB activity is involved in the pathogenesis of AMD, a chronic inflammatory disease of the eye, is still not known. This present study hypothesized that extracellular GzmB may affect the function of the outer blood-retina barrier (oBRB) and BM remodeling by cleaving potential substrates in the outer retina. In order to test this hypothesis, this study used immunohistochemistry (IHC) to identify increased numbers of GzmB+ choroidal cells in aged and CNV human ocular tissues, most of which were confirmed to be choroidal mast cells. RPE cells were also found to be another source of GzmB in the outer retina. This study then used cell culture methods and immunocytochemistry (ICC) and western blot to show that exogenous GzmB cleaves RPE cell-cell adhesion proteins (ZO-1, JAM-A, occludin) and RPE-derived extracellular matrix (ECM) substrates (fibronectin, laminin), leading to damaged RPE barrier function and the degradation of ECM components in BM in vitro. These results support the hypothesis that extracellular GzmB may play a role in disrupting the oBRB function and BM remodeling. This study is the first to explore such pathophysiological implications of extracellular GzmB activity in AMD.
View record
Membership Status
Member of G+PS
View explanation of statuses
Location
Program Affiliations
Academic Unit(s)
If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.